Magnesium Treatment in Hypoparathyroidism
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00824226 |
Recruitment Status :
Completed
First Posted : January 16, 2009
Last Update Posted : August 29, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypoparathyroidism | Dietary Supplement: magnesium | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | August 2011 |

- Dietary Supplement: magnesium
magnesium 350 mg tablets once a day for 3 weeks
- Calcium level at the end of magnesium treatment compared to pretreatment level [ Time Frame: 3 weeks ]
- Calcium level after stopping treatment compared to the level at the end of magnesium treatment [ Time Frame: 2 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- primary or secondary hypoparathyroidism
- treatment with calcium plus vitamin D analogue
- ionized calcium 1,0-1,29 mmol/L
- magnesium level 0,7-1,05 mmol/L
- TSH 0.1- 10 imU/L
Exclusion Criteria:
- any other disease known to influence plasma Ca level
- pregnancy
- creatinine > 150 microM/L
- patient has used supplementary magnesium within 2 previous months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824226
Estonia | |
Tartu University Hospital | |
Tartu, Estonia, 50406 |
Principal Investigator: | Vallo Volke, MD, PhD | University of Tartu, Institute of Physiology |
Responsible Party: | Vallo Volke, Dr., University of Tartu |
ClinicalTrials.gov Identifier: | NCT00824226 |
Other Study ID Numbers: |
UT296 |
First Posted: | January 16, 2009 Key Record Dates |
Last Update Posted: | August 29, 2011 |
Last Verified: | August 2011 |
primary hypoparathyroidism secondary hypoparathyroidism magnesium |
Hypoparathyroidism Parathyroid Diseases Endocrine System Diseases |